Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease.
Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action.
Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.
Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, and additional manufacturing capability in Frankfurt, Germany.
Company Details
- Founded
- -
- Address
- 45 Pont Street, London,sw1x 0bd,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- rexgenero.com
- HQ
- LONDON
Ixaka Questions
Ixaka's website is rexgenero.com
Ixaka's LinkedIn profile is https://uk.linkedin.com/company/ixaka-limited
Ixaka's industry is
Biotechnology Research
Ixaka's top competitors are
Biomedal,
Invectys,
Altruist Biologics,
Qkine,
Texcell,
Theravectys,
Alaya.bio,
Erenacare,
Genethon,
Angle.
Ixaka's categories are Biotechnology Research
Ixaka's founding year is 2015
